SG11201408617PA - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Info

Publication number
SG11201408617PA
SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA
Authority
SG
Singapore
Prior art keywords
alkyl
international
con
treatment
heterocyclyl
Prior art date
Application number
SG11201408617PA
Inventor
Johann Leban
Mirko Zaja
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of SG11201408617PA publication Critical patent/SG11201408617PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/001464 A1 (51) International Patent Classification: C07D 491/02 (2006.01) A61P 25/00 (2006.01) A61K31/4188 (2006.01) A61P 29/00 (2006.01) A61K35/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/063537 27 June 2013 (27.06.2013) English (30) Priority Data: 61/664,936 12174669.7 27 June 2012 (27.06.2012) 2 July 2012 (02.07.2012) English US EP (71) Applicant: 4SC DISCOVERY GMBH [DE/DE]; Am Klopferspitz 19a, 82152 Planegg-Martinsried (DE). (72) Inventors: LEBAN, Johann; Pyrkergasse 31, Appartment 10, A-1190 Wien (AT). ZAJA, Mirko; Horwarthstr. 33, 80804 Munchen (DE). (74) Agent: BOEHMERT & BOEHMERT; Hollerallee 32, 28209 Bremen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CAN­ CER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS Y L- <*) •t •t i-H o o o CJ O & (57) Abstract: The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, (I) wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R\" as defined herein, *-N(R'\")CO-, *- CON(R'\")-, *-N(R\")CON(R\"')-, , -S-, -SO-, *-N(R'\")-, *-N(R'\")CO-, *-CON(R'\")-, -CO-, *-COO-, *-OOC-, *-S02N(R'\")-, -S0 , 2 or *- N(R'\")-S02-, wherein R'\" is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more R x further described herein; L is a bond or *-N(R )CO-, N *-CON(R )-, N *- N(R )-, N *-C=N(R )-, *-N(R )-alkyI-, *-alkyl-N(R )-, *-N(R )CON(R )-, *-CO-, *-S0 -, N N N N N 2 alkyl, *-alkyl-0-alkyl-, *-NCO-CH=CH-, *- CH=CH-CONH-, * -S0 N(R )-, *-N(R )S0 -, 2 N N 2 or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more R Y further described herein; and R and R N are further described herein; as well as their use as a medicament, a pharmaceutical composition comprising them, method of a treat - ment or prevention of medical a condition entailing the administration thereof, and the use thereof in the manufacture of medica a - ment for the treatment or prevention of medical condition, particularly autoimmune a inflammatory disorders, CNS disorders, sleep - ing disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.
SG11201408617PA 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders SG11201408617PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664936P 2012-06-27 2012-06-27
EP12174669 2012-07-02
PCT/EP2013/063537 WO2014001464A1 (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Publications (1)

Publication Number Publication Date
SG11201408617PA true SG11201408617PA (en) 2015-01-29

Family

ID=49782305

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408617PA SG11201408617PA (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Country Status (19)

Country Link
US (2) US9580438B2 (en)
EP (1) EP2867237A1 (en)
JP (2) JP6272846B2 (en)
KR (1) KR102155559B1 (en)
CN (1) CN104540831B (en)
AU (2) AU2013283318B2 (en)
BR (1) BR112014032581A8 (en)
CA (1) CA2877589C (en)
EA (1) EA029718B1 (en)
HK (1) HK1204474A1 (en)
IL (1) IL236463A0 (en)
IN (1) IN2014MN02562A (en)
MX (1) MX350418B (en)
MY (1) MY167785A (en)
NZ (1) NZ702618A (en)
SG (1) SG11201408617PA (en)
UA (1) UA116541C2 (en)
WO (1) WO2014001464A1 (en)
ZA (1) ZA201409194B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014001464A1 (en) * 2012-06-27 2014-01-03 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CN106661027B (en) 2014-03-20 2019-12-24 卡佩拉医疗公司 Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
HRP20220936T1 (en) * 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
KR20200090154A (en) 2017-10-27 2020-07-28 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 Composition and method for modulating immune response by activation of alpha protein kinase 1
BR112021003665A2 (en) 2018-09-13 2021-05-18 Bayer Aktiengesellschaft heterocyclene derivatives as pest control agents
CN109020990A (en) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 Phenyl benzofurans compound, and preparation method thereof, composition and medical usage
KR102119150B1 (en) * 2018-10-23 2020-06-04 한국원자력의학원 A pharmaceutical composition for preventing or treating cancer comprising as an active ingredient N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl)
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
JP7327855B2 (en) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 METHOD FOR SELECTING CANCER PATIENTS FOR EFFECTIVE RETINOID AND CANCER THERAPEUTIC COMBINATION THERAPY AND COMBINATION MEDICINE OF RETINOID AND CANCER THERAPEUTIC
CN116942819A (en) * 2023-04-24 2023-10-27 珠海市人民医院 Application of microtubule-associated serine/threonine-like kinase inhibitor in preparation of medicines for treating tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167569A (en) 1976-12-09 1979-09-11 Imperial Chemical Industries Limited Pyrimido[1,2-a ]benzimidazole derivatives
ATE511840T1 (en) 2001-10-09 2011-06-15 Amgen Inc IMIDAZOLE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JO2724B1 (en) 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-substituted-5- and 6-Aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I
WO2006130673A1 (en) * 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP1957078B1 (en) 2005-12-02 2013-08-28 Bayer HealthCare, LLC Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
PE20080403A1 (en) * 2006-07-14 2008-04-25 Amgen Inc FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
FR2918061B1 (en) 2007-06-28 2010-10-22 Sanofi Aventis 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
SG10201501272SA (en) * 2009-10-22 2015-04-29 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
WO2014001464A1 (en) * 2012-06-27 2014-01-03 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Also Published As

Publication number Publication date
IN2014MN02562A (en) 2015-07-24
HK1204474A1 (en) 2015-11-20
AU2018201275A1 (en) 2018-03-15
MX350418B (en) 2017-09-06
EA029718B1 (en) 2018-05-31
CN104540831A (en) 2015-04-22
JP2015525742A (en) 2015-09-07
BR112014032581A8 (en) 2018-08-14
KR102155559B1 (en) 2020-09-15
NZ702618A (en) 2016-12-23
WO2014001464A1 (en) 2014-01-03
JP6272846B2 (en) 2018-01-31
US20150158878A1 (en) 2015-06-11
EP2867237A1 (en) 2015-05-06
EA201500050A1 (en) 2015-09-30
US9580438B2 (en) 2017-02-28
CN104540831B (en) 2017-11-07
MY167785A (en) 2018-09-25
BR112014032581A2 (en) 2017-06-27
CA2877589A1 (en) 2014-01-03
MX2014015938A (en) 2015-07-21
JP2018076360A (en) 2018-05-17
CA2877589C (en) 2019-11-26
ZA201409194B (en) 2017-08-30
IL236463A0 (en) 2015-02-26
US20170240556A1 (en) 2017-08-24
AU2013283318B2 (en) 2017-11-23
KR20150037877A (en) 2015-04-08
AU2013283318A1 (en) 2015-01-22
UA116541C2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201408094YA (en) Neprilysin inhibitors
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201407837WA (en) Beta-hairpin peptidomimetics
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201402986RA (en) Kinase inhibitors
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201809674QA (en) Adenine derivatives as protein kinase inhibitors
SG11201908235RA (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201805142RA (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative